NetworkNewsBreaks – Adaptimmune Therapeutics plc (NASDAQ: ADAP) Closes $259.3M Follow-On
Adaptimmune Therapeutics (NASDAQ: ADAP), a leader in cell therapy to treat cancer, recently closed an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”), including 3,075,000 additional ADSs in accordance with the full exercise of the over-allotment option granted to the underwriters, resulting in gross proceeds of approximately $259.3 million. The ADSs were sold at the public offering price of $11.00 each. The company intends to utilize the proceeds from the offering towards advancing the development of its immunotherapies into and through clinical trials and for general corporate purposes. ROTH Capital Partners acted as lead manager for the…







